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Abstract: 
 
Epithelial Ovarian Carcinoma (EOC) is a disease with poor prognosis, most often diagnosed at an advanced 
stage, thus necessitating aggressive and complex surgery. The aim of this study was to compare 
Progression Free Survival (PFS) at 1st line treatment of EOC patients treated in high vs low -volume 
hospitals. This retrospective study using prospectively implemented databases was conducted o n an 
exhaustive cohort of 267 patients treated in first line during 2012 in the Rhone -Alps Region of France. In 
order to control for selection bias, a multivariate analysis and the Inverse Probability Weighting (IPW) using 
the propensity score were adopted. An Adjusted Kaplan Meier Estimator (AKME) and a univariate Cox model 
in the weighted sample were then applied in order to determine the impact of the centralization of care on 
EOC. Patients treated in lower volume hospitals had a probability of relapse ( including death) that was 1.5 
times higher than for patients treated in higher volume hospitals (p=0.02). As reported in other countries, the 
concentration of care for EOC has a significant positive impact on patient outcomes. 
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Abstract 
Epithelial Ovarian Carcinoma (EOC) is a disease with poor prognosis, most often diagnosed at an 
advanced stage, thus necessitating aggressive and complex surgery. The aim of this study was to 
compare Progression Free Survival (PFS) at 1st line treatment of EOC patients treated in high vs low-
volume hospitals. This retrospective study using prospectively implemented databases was conducted 
on an exhaustive cohort of 267 patients treated in first line during 2012 in the Rhone-Alps Region of 
France. In order to control for selection bias, a multivariate analysis and the Inverse Probability 
Weighting (IPW) using the propensity score were adopted. An Adjusted Kaplan Meier Estimator 
(AKME) and a univariate Cox model in the weighted sample were then applied in order to determine 
the impact of the centralization of care on EOC. Patients treated in lower volume hospitals had a 
probability of relapse (including death) that was 1.5 times higher than for patients treated in higher 
volume hospitals (p=0.02). As reported in other countries, the concentration of care for EOC has a 
significant positive impact on patient outcomes. 
 
Keywords:  Counterfactual; Disease management programme; France; Epithelial Ovarian Cancer; 
Propensity score; Centralization of care. 
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1. Introduction 
Observational studies are increasingly being used in the health care sector, for several reasons. It is 
sometimes impossible to randomize the affectation to treatment for practical or ethical reasons.  It is 
often the case in retrospective studies analyzing the care pathway. In this context of observational data, 
we must take into account the selection bias due to the sample heterogeneity [1]. Indeed, a selection 
bias, or recruitment bias, could emerge since participation to the treatment is also not random - some 
kinds of patients have a higher probability of being treated than others. Several well-known methods 
can be used to solve this issue, such as stratification or multivariate analysis, and more sophisticated 
method are more and more used such as matching methods,  instrumental variable, regression by 
discontinuity and difference in difference.  
Epithelial ovarian carcinoma (EOC) is a serious disease which extend is still underestimated due to a 
rather low incidence and a significant mortality. The EOC remains the eighth cancer sorted by frequency 
order for women, with an incidence of 7.9 for 100 000 persons/year. EOC remains the main gynecologic 
cancer death cause in industrialized countries with a mortality rate in France estimated to 4/100 000 
persons per year [2]. Relapse-free survival and overall survival of patients are related to the 
characteristics of the disease, the patient herself and the disease management. Several recent 
retrospective studies investigated the relationship between outcomes of ovarian cancer treatment and 
type of care provider [3]. The results showed a better quality of surgery when performed by 
“gynaecologic oncologists” in specialized hospitals (referent centers) and only small differences in 
chemotherapy regimens between the settings.  Some studies [4-14] also investigated the impact of 
centralization of care, in terms of volume, in patients’ outcomes. Patients are more likely to be optimally 
debulked in a high volume hospital or in a specialized provider. These studies also showed that patients 
have better survival outcomes in high volume hospital. But most of these studies focus on high stage 
disease, and none have been done in France. The majority of patients with ovarian cancer do not receive 
care in specialized settings.  
The aim of this study was to compared Progression Free Survival (PFS) in 1st line treatment of EOC 
patients treated in high (HVH) versus low (LVH) volume hospitals taking into account all prognostic 
factors. To that end, we used observational data, and thus have to control for cofounder factor. 
All Counterfactual methods are not always applicable depending on the context, database and are based 
on different hypotheses. For difference in difference method, we need to observe patients before and 
after treatment (longitudinal data) in order to compare the outcome of each patient before and after 
treatment, and between treated and untreated patients. This method was not applicable in our case 
because we had cross sectional data. With regression by discontinuity, patients on either side of the 
threshold to define high volume hospitals are considered almost identical, and thus, can be compared in 
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order to estimate the treatment effect. This method requires a large dataset which was not the case in 
our study. The Instrumental Variable method treats the endogeneity of the treatment variable directly in 
the regression. But this method requires to find a good and valid instrument, which is a variable strongly 
correlated to the treatment variable and uncorrelated to the outcome. This method was not applicable 
because such a variable was not available in our database. Finally, we used multivariate analysis and 
matching methods in order to treat the selection bias because they are less restrictive in terms of sample 
size and are applicable with cross sectional data. 
 
2. Counterfactual methods 
2.1. Different types of treatment effect: marginal versus conditional and relative versus 
absolute 
The multivariate analysis allows one to estimate a conditional effect; it is the average effect of being 
treated in higher volume hospital at the individual level, as if a patient in a low volume hospital was 
treated in a higher volume hospital. It differs from the marginal treatment effect, which is the difference 
in outcome between the groups of patient in high versus low volume hospital [15]. But, to estimate the 
marginal treatment effect, we needs that the two groups are identical in all aspects, except of being 
treated in a high-low volume hospital. In a RCT, it is possible to estimate the marginal treatment effect 
by simple difference in outcome because the randomization balances the covariates, but it is impossible 
in observational studies with time to event outcome because the conditional differs from the marginal 
treatment effect. Moreover, Austin PC (2014) [15] made some recommendation in the estimation of a 
treatment effect in an observational study. He recommends to estimate both absolute and relative 
measure of treatment, as the CONSORT statement recommendation for a RCT with a dichotomous 
outcome. Again, multivariate analysis allows one to estimate a relative effect, while it is possible to 
estimate both absolute and relative treatment effect with a propensity score approach. Indeed, the 
estimation of the treatment effect in observational studies should mimic treatment effect estimation in a 
RCT. And in a RCT, the conditional effect equal the marginal effect, so we should find similar results 
if the selection into treatment is based only on observable characteristics. If not, it could be due to 
unobserved characteristics interacting in the estimation of the treatment effect, and lead to different 
treatment effect. 
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2.2. Multivariate analysis 
One common approach when dealing with cofounding factor is to use multivariate regression [1]. The 
principle was to regress the survival time on the treatment variable (an indicator variable denoting high 
or low volume hospital) and a set of patients’ characteristics. In practice, we first ran a Cox proportional 
hazard model of the Progression Free Survival (PFS) on the set of covariates, and then tested whether 
the hazard is proportional or not by the Schoenfeld residual test. Then, if the proportional hazard 
assumption holds, the model to prefer is a semi parametric Cox proportional hazard regression. If not, 
we turned out on a parametric estimation of an accelerated failure time (AFT) model. With AFT model, 
we had to choose a parametric distribution of the hazard. A common practice was to estimate, at first, a 
Generalized Gamma model. The density function is given in equation (1). 
𝑓(𝑡) =
𝛾𝜎(𝛾𝑡)𝜎𝑘−1𝑒−(𝛾𝑡)
𝜎
Γ(𝑘)
    (1) 
With 𝛾𝑖 = 𝑒
−(𝑋𝑖𝛽),  and k and 𝜎  are parameters linked to the hazard’s function. The Generalized Gamma 
distribution includes the Exponential (𝑘 = 𝜎 = 1), Weibull (𝑘 = 1), Lognormal (𝑘 = 0) and Gamma 
(𝜎 = 1) distributions. Then, it was possible to test for these parameters in order to choose between these 
distributions by a likelihood ratio test. 
 
2.3. Propensity score matching using the inverse probability weighting (IPW) 
In order to estimate the marginal effect of being treated in a high volume hospital, matching methods 
can be used. There are many different matching methods, but two simulations studies (Handouyahia A. 
et al [16], Austin PC (2013) [17]) had shown that the IPW seems to performs better in estimating the 
marginal hazard ratio of the treatment effect, compared with other matching methods using the 
propensity score.  
The IPW method balances the covariate of the two groups by weighting all patients of the data base by 
the inverse of the propensity score. The propensity score was the conditional probability for a patient to 
be treated in a high volume hospital, conditionally to observables characteristics. This probability is 
estimated by a logit model of an indicator variable denoting high or low volume hospital on a set of 
covariates. The standardized difference in mean is recommended to compare the baseline characteristics, 
instead of t-test [15, 18].  
The stabilized weighted of the IPW proposed by J.M. Robins [19] can be used in order to reduce the 
volatility of the weights. Note 𝑇𝑖  the treatment variable, 𝑝𝑖 the propensity score and 𝑓(𝑇) the distribution 
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of the treatment estimate by another logit model. In order to estimate the Average Treatment effect on 
the Treaties (ATT), weighted can be calculated with the formula in equation (2). 
𝑤𝑖
𝐴𝑇𝑇 = 𝑓(𝑇) ∗ [ 𝑇𝑖 +
𝑝𝑖(1−𝑇𝑖 )
(1−𝑝𝑖)
]    (2) 
An Adjusted Kaplan Meier Estimator (AKME), proposed by Xie and Liu [20] and a univariate Cox 
model in the weighted sample, as described by Cole and Hernan [21], were then applied in order to 
determine respectively the absolute and relative impact of the concentration of care on EOC. We used 
the robust variance estimator of Lin and Wei [22] for the weighted Cox model and the Cox test of 
equality for the AKME, to take into account the within matched set correlation due to matching. Patients 
in high versus low volume hospital are not anymore independent after matching using the IPW, because 
they are linked by their propensity score. Indeed, two patients with similar propensity score will have 
similar characteristics, and patients’ characteristics are strongly correlated with outcome.  
 
3. Application  
3.1 Study design 
This retrospective study using prospectively implemented databases was conducted on an exhaustive 
cohort of patients treated in first line during 2012 in the Rhone-Alps Region of France. The inclusion 
criteria were to have been in 1st line treatment of Epithelial Ovarian Cancer (EOC), diagnosed in 2012, 
incident case, more than 18 years old, residency in France. The exclusion criteria were non-epithelial 
disease, relapse disease or being less than 18 years old. The study was conducted in accordance with the 
ethical principles for medical research involving human subjects developed in the Declaration of 
Helsinki by the World Medical Association (WMA). The study received approval in France from the 
National Ethics Committee (N°909226) and the National Committee for Protection of Personal Data 
(N°09-203).  
Several international studies [4-14] have used a threshold to define a high volume hospital between 10-
20 cases per year for EOC. But, it appears that the median of the volume of patients treated in a hospital 
per year in the Rhone-Alpes region of France is 4. And on average, hospital in the region considered in 
this study had treated less than 6 patients per year in 2012. Therefore, we considered a threshold of 10 
patients treated for EOC per year in primary care, which is strict enough in the case of France and which 
has also been used by Mercado C et al (2010) [8], Bristow RE et al (2015) [6]. Thus, 90% of hospital 
had treated less than 10 patients per year in the region in 2012. Different countries need different 
threshold to define a high volume hospital, according to its prevalence of the disease. For example, the 
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mean volume activity of high volume hospital in the study of Ioka A et al (2004) [9] on a Japanese 
dataset was 8.8, which can seems low compared to American studies. 
 
3.2 Patient’s characteristics 
In 2012, 267 patients were identified with an EOC in the region, but only 231 were used in modelization 
because of missing data. Patients were treated by 49 different hospitals in the region. The median volume 
activity by hospital is 4 patients treated for EOC per year. Volume activity is disparate among hospital, 
from a minimum of 1 patient to a maximum of 42 patients in 2012. N=98 (37%) patients in 1st line 
setting for EOC in the region have been treated in a high volume hospital.  
 
Table 1 : Characteristics of the patients 
 
 Low volume 
hospital (n=98) 
High volume 
hospital (n=169) 
  
 m 𝜎 m 𝜎 P-value %bias 
Age 63.68 13.79 65.80 12.09 0.205 16.4 
Cancer history  13.60 0.34 17.34 0.38 0.411 10.03 
Ascites  59.76 0.49 67.34 0.47 0.218 15.7 
Histology :  
- HGSC & undiff 52.25 0.50 59.14 0.49 0.294 13.8 
- SLG 7.09 0.25 3.22 0.17 0.203 -17.5 
- Muccinous 9.67 0.29 4.30 0.20 0.124 -21.1 
- Endometrioid 15.48 0.36 10.75 0.31 0.296 -14.0 
- Clear cell 5.91 0.23 5.10 0.22 0.781 -3.6 
- Unknown 9.03 0.28 17.20 0.37 0.056 24.3 
FIGO Stage :  
- I 25.44 0.43 15.46 0.36 0.058 -24.8 
- II 5.32 0.22 7.21 0.26 0.534 7.8 
- III 55.62 0.49 65.97 0.47 0.098 21.3 
- IV 13.60 0.34 11.34 0.31 0.595 -6.8 
Tumor Grade :       
- 1 18.05 0.38 4.54 0.20 0.002 -43.5 
- 2 20.83 0.40 16.63 0.34 0.168 -19.1 
- 3 61.11 0.48 81.81 0.38 0.000 46.9 
     mean  19.2 
     median
  
16.9 
m : mean (frequency) if the covariate is continuous (binary) / 𝜎 : standard deviation 
SLG : Serous of Low Grade ; HGSC & undiff : High Grade Serous Carcinoma & undifferentiated 
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At baseline (i.e. before matching), patients treated in higher volume hospital seem to have a higher tumor 
grade at a 5% level of significance, and higher FIGO stage at a 10% level of significance, compare with 
patients treated in lower volume hospital (table 1). On the other hand, there are no significant difference 
between patients in high versus low volume hospital in terms of age, ascites and history of cancer. More 
details are provided in table 1. 
 
3.3 Standard Kaplan Meier estimator 
In the health care sector, not all studies take into account the selection bias in statistical analysis. In our 
case, a simple way to estimate the treatment effect without solving the recruitment bias issue is to 
estimate a standard Kaplan Meier estimator for each group of patient. Then, we can compare the two 
survivals curves with a log rank test in order to see if the difference is significant. This naïve estimation 
of the treatment effect is given by figure 1.  
 
 
Figure 1: Standard Kaplan Meier estimator of the PFS 
 
This estimation of the treatment effect is based on a sample homogeneity assumption. It appears in figure 
1 that the PFS is not statistically different in high than in low volume hospital. But it is clear that this 
estimation is biased by the selection bias. Indeed, survival in high and in low volume hospital seems to 
be comparable, while high volume hospitals are treated patients of higher stage and grade of the disease.  
3.4 Multivariate analysis approach 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 10 20 30 40
analysis time
Low Volume Hospital (LVH) High Volume Hospital (HVH)
Log-Rank Test : p-value = 0.7271
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The Schoenefeld residual test showed that the proportional hazard assumption did not holds (p=0.0804). 
Thus, the model is not applicable and we turn out in a parametric estimation of an AFT model. It appears 
that the Weibull distribution fitted best our data. We chose Weibull instead of Gompertz and Loglogistic, 
which are not a particular case of the generalized gamma, because the AFT model with a Weibull 
distribution minimized the Akaike Information Criterion (AIC). Table 2 shows that patients treated in 
higher volume hospital have a higher PFS at a 10% level of significance than patients in lower volume 
hospital, on average and all other things being equal. 
 
Table 2 : A Weibull accelerated failure time model on PFS 
 
 Coefficient 
 
𝜎 P-value 
High volume hospital 0.23 0.130 0.066 
Age -0.01 0.005 0.012 
Cancer history  -0.23 0.155 0.132 
Ascites  -0.33 0.148 0.026 
Histology :  
- HGSC & undiff Ref Ref Ref 
- SLG 0.20 0.499 0.678 
- Muccinous 0.17 0.466 0.713 
- Endometrioid 0.25 0.258 0.316 
- Clear cell -0.07 0.285 0.793 
- Unknown -0.19 0.215 0.362 
FIGO Stage :  
- I 1.02 0.314 0.001 
- II 0.63 0.336 0.060 
- III 0.31 0.166 0.057 
- IV Ref Ref Ref 
Tumor Grade :  
- 1 0.01 0.423 0.964 
- 2 -0.09 0.157 0.527 
- 3 Ref Ref Ref 
𝜎 : standard deviation / Ref : modality in reference 
SLG : Serous of Low Grade ; HGSC & undiff : High Grade Serous Carcinoma & 
undifferentiated 
 
 
3.5 Propensity score approach  
In order to control for the selection bias, to estimate both a relative and an absolute treatment effect and 
that this treatment effect is a marginal effect, we used the Inverse probability weighting using the 
propensity score (IPW). Table 3 shows a good quality of the matching by the IPW. Indeed, there is no 
significant difference for all covariates between the two groups, while there were significant differences 
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prior matching for stage, grade and histology. The mean standardized difference in mean is 1.7 for the 
matched sample (Cf table 3) instead of 19.2 for the unmatched sample (Cf table 1). Moreover, the 
common support of the distribution of the propensity score is sufficient to valid the overlap assumption 
(figure 2). Indeed, the distribution of the propensity score for treated and untreated patients showed that 
none treated patients were excluded of the matching because of their propensity score. 
 
Figure 2 : Distribution of the propensity score 
 
Matching using the IPW allow to estimate both the absolute treatment effect, with the AKME, and the 
relative reduction of an event occurring by the univariate weight cox model. Figure 3, based on the 
AKME, shows that patients in high volume hospital have a significant higher PFS (p=0.020) than 
patients in lower volume hospital. The median of the volume activity is 19.1 for high volume hospital 
instead of 14.1 for low volume hospital. 
 
 
 
 
 
Figure 3: AKME of PFS after matching using the inverse probability weighting (ATT weight) 
0 .2 .4 .6 .8
Propensity Score
Untreated Treated
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Table 3: Characteristics of the patients after using IPW matching 
 
 High 
volume 
hospital 
(n=144)  
Low 
volume 
hospital 
(n=87)  
  
 m m Pvalue %bias 
Age 65.97 65.39 0.822 -4.5 
Cancer history  18.50 18.39 0.989 -0.3 
Ascites  66.50 66.66 0.986 0.3 
Histology :     
- HGSC & undiff 62.62 63.21 0.953 1.2 
- SLG 3.17 3.44 0.941 1.3 
- Muccinous 3.52 3.44 0.984 -0.3 
- Endometrioid 10.82 11.49 0.919 2.0 
- Clear cell 6.45 5.74 0.885 -3.1 
- Unknown 13.39 12.64 0.914 -2.2 
FIGO Stage :     
- I 15.77 16.09 0.967 0.8 
- II 8.53 8.04 0.932 -2.0 
- III 65.24 64.36 0.930 -1.8 
- IV 10.44 11.49 0.873 3.2 
Tumor Grade :     
- 1 4.23 4.59 0.933 1.2 
- 2 13.18 13.79 0.932 1.6 
- 3 82.58 81.60 0.903 -2.2 
         Mean : 1.7 
            Median : 1.7 
m : mean (frequency) if the covariate is continuous (binary) / 𝜎 : standard deviation 
/ %bias, also call standardized difference in mean 
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Furthermore, the univariate Cox model of the PFS, weighted by the inverse of the propensity score, 
reveals that the hazard ratio of being treated in a high volume hospital is 0.65 (p=0.020). The Schoenfeld 
residual test reveals that the proportional hazard assumption is valid for the univariate weighted Cox 
model, and confirms the robustness of the result. Thus, patients treated in lower volume hospitals have 
a probability of relapse (including death) 1.5 times higher compared with patients treated in higher 
volume hospitals (p=0.02).  
 
 
4. Conclusion 
Patients treated in high versus low volume hospital aren’t similar (table 1). Thus, we expect the presence 
of selection bias, which means that the participation into treatment (i.e. being treated in a high volume 
hospital) is not random [1]. In other word, some types of patients are more likely to be treated in high 
volume hospital than other, and this must be taking into account in order to estimate a proper treatment 
effect.  
Propensity score approach is based on less constraining assumption than multivariate analysis [23]. 
Indeed, propensity score and multivariate analysis are based on the conditional independence 
assumption (CIA), which tells that conditionally on observed covariates, patients are treated in a high 
or low volume hospital randomly. But multivariate analysis requires stronger assumption about the 
distribution of the covariates and their relation with the relapse free survival. In our case, we also had to 
choose a distribution of the hazard in order to fit a parametric AFT model of the progression free survival 
on a variable denoting treatment and on a set of covariates because the proportional hazard assumption 
was violated.  
Therefore, the combination of a multivariate analysis and a matching method allow one to estimate both 
conditional and marginal effect of being treated in a high volume hospital and to prove the robustness 
of our findings. The conditional effect tells us that if a patient treated in a lower hospital was treated in 
a higher volume hospital, this would on average improve her progression free survival (p=0.066). 
However, the marginal treatment effect tells us that patients treated in higher volume hospital have a 
probability of relapse (including death) 1.5 times inferior to patients treated in lower volume hospital 
(p=0.020) and that the absolute difference of survival is significant (p=0.020) (See figure 3). We can be 
confident about the robustness of our result, because both the parametric (AFT model) and non-
parametric (propensity score) approach led to similar results.  
Many countries already require a minimum activity for a hospital to have the authorization for cancer 
treatment. In France, the minimum cutoff in order to have an authorization to treat gynecologic cancer 
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is defined by the French ministerial order of the 27 march 2007 at 20 surgeries per year. Below this 
volume of activity, a hospital cannot treat patients with gynecologic cancer. But this threshold takes into 
account all different kind of gynecologic cancer, such as cervical, ovarian, vaginal, uterine and vulvar 
cancer. Our findings would suggest that there is a need of a specific minimum activity cutoff only for 
ovarian cancer. Indeed, the global threshold of 20 cases per year does not assure a sufficient activity for 
each disease include in gynecologic cancer. In the Rhone-Alps Region of France, 63% of patients treated 
in primary care in 2012 were treated in a hospital with less than 10 cases per year, and 24% in a hospital 
with less than 5 cases per year. Our findings would encourage the use of a specific cutoff for ovarian 
cancer, and more research need to be done for other rare cancers in order to see if a specific minimum 
activity cutoff is needed too.  
As reported in other countries [4-14], the concentration of care for EOC has a significant positive impact 
on patient relapse free survival. High volume hospitals are mostly treated advanced stage EOC, while it 
is clear that the concentration of care improve patient survival for both advanced and early EOC. More 
research needs to be done with dynamic treatment methods in order to take into account the entire care 
pathway. Indeed, in our study, we only considered the hospital of 1st line treatment which is the one of 
primary interest because the 1st line surgery is strongly correlated with survival. But it would be 
interesting to see how the effect of volume goes on outcomes if we considered hospitals which are 
treating relapse disease. More research also need to be done on the cost associated with the concentration 
of care and on the likely simultaneous causality between volume and survival. 
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